PROJECT SHEET – COLLECTIVE INFORMATION FOR DATA SUBJECTS

Official title	**SUCCESS: Follow-up schedules after non-metastatic breast cancer: personalization and impact on prognosis**
Condition	Breast cancer
Contact	University of Zurich: elise.dumas@uzh.ch French National Cancer Institute: lesdonnees@institutcancer.fr

Project description

Background: Breast cancer is the most common cancer among women, with 2.3 million new cases worldwide in 2022. Advances in screening and treatment have significantly improved survival rates, leading to an increase in the number of BC survivors. However, women with a history of early-stage BC remain at a significant risk of recurrence throughout their lives and face specific challenges regarding medical follow-up, late effects of treatment, and quality of life. After initial treatment—typically involving surgery, chemotherapy, and/or radiation therapy—patients with early-stage breast cancer enter a surveillance program that includes regular medical checkups and mammograms for at least five years. Follow-up care may be provided exclusively at the hospital, exclusively in the community, or shared between the hospital and the community. Screening for metastatic recurrence using imaging procedures is not part of current follow-up recommendations for asymptomatic patients. In the absence of recent data from clinical trials, the optimal follow-up schedule—particularly for the detection of metastatic disease—remains uncertain.

Objectives: In this project, real-world data will be analyzed using modern causal inference methods to propose recommendations aimed at improving patient care following initial treatment for early-stage breast cancer. More specifically, this project aims to improve the early detection of locoregional, contralateral, and distant recurrences by designing optimal, personalized follow-up schedules and by investigating how outpatient care data could be integrated to detect metastatic recurrences early.

Methodology: SUCCESS is an observational study using SNDS ("*Systeme National des Données de Santé*") data from the French National Cancer Institute data warehouse (EDS-RNC data).

Study population: Adult women diagnosed with incident non-metastatic breast cancer between 01/01/2011 and 31/12/2027 and treated at least with breast surgery.

Data used: EDS-RNC data: including patient characteristics (age, area of residence, deprivation index, CMU-C registration), diagnosis dates, treatments (surgery,

chemotherapy, radiotherapy, target therapy, endocrine therapy), tumor characteristics (inferred from received treatment and diagnostic codes), comorbidities, deaths, causes of death (when available), recurrences, surveillance examinations and consultations, and healthcare costs (data origin: SNDS).

No other data will be used. No linkage with external data.

Project agenda

Study conduct period: October 2025 - March 2030.

Results availability: Ongoing study.

Data retention: 5 years in the project space; 20 years in the EDS-RNC.

Administrative and legal information

Project lead: University of Zurich (EBPI). Contact: elise.dumas@uzh.ch

Participating teams: Team 1. University of Zurich (responsibility: project conduct);

Team 2. French National Cancer Institute (responsibility: data provider).

Regulatory framework: CNIL authorization No. 2026-057.

Legal basis: Legitimate interest (GDPR Art. 6(1)(f)) and scientific research (GDPR Art. 9(2)(j)).

Exercise of rights: The individuals concerned may exercise their rights of access, objection, rectification, restriction, and erasure in accordance with the procedures set out at https://lesdonnees.e-cancer.fr/, as well as lodge a complaint with the CNIL.

Data protection contact : privacy@rud.uzh.ch ; dpo@institutcancer.fr